Oxford Biomedica plc / Fundamentals
Income statement
- Net revenue
€251.60M - Cost of goods sold
€145.12M - Gross profit
€106.48M - SG&A expenses
€61.46M - R&D expenses
€154.68M - EBITDA
-€90.38M - D&A
€51.83M - EBIT
-€262.42M - Interest expenses
€14.54M - EBT
-€271.71M - Tax expenses
€7.31M - Net income
-€231.25M
Cash flow statement
- Net deferred tax
-€18.05M - Non-cash items
€91.25M - Changes in working capital
-€826.23K - Operating cash flow
-€95.00M - Capex
€19.97M - Other investing cash flow
€18.13M - Net investing cash flow
€5.25M - Total cash dividends paid
€0.00 - Issuance of common stock
€20.95M - Debt repayment
-€3.43M - Other financing cash flow
-€723.67K - Net financing cash flow
-€3.06M - Foreign exchange effects
€769.76K - Net change in cash
€50.52M - Cash at end of period
€69.89M - Free cash flow
-€75.03M
Balance sheet
- Cash and cash equivalents
€69.89M - Cash and short-term investments
€69.89M - Total receivables
€48.53M - Inventory
€15.64M - Other current assets
€19.43M - Total current assets
€153.48M - Property, plant & equipment
€74.09M - Goodwill
€0.00 - Intangible assets
€33.67M - Long-term investments
€0.00 - Other non-current assets
€5.69M - Total non-current assets
€113.45M - Total assets
€266.93M - Accounts payable
€11.08M - Short-term debt
€323.81K - Other current liabilities
€55.81M - Total current liabilities
€67.21M - Long-term debt
€120.24M - Deferred tax liabilities
€0.00 - Other non-current liabilities
€8.55M - Total non-current liabilities
€130.02M - Total liabilities
€197.23M - Common stock
€61.05M - Retained earnings
-€460.36M - Other equity
€0.00 - Total equity
€69.70M - Total liabilities and shareholders' equity
€266.93M
Company information
- Market capitalization
€318.52M - Employees
861 - Enterprise Value
€398.80M
Company ratios
- Gross margin
-
42.3% Much better than peer group: 22.3% - EBITDA margin
-
-35.9% Worse than peer group: -26.6% - EBIT margin
-
-104.3% Worse than peer group: -92.5% - EBT margin
-
-108.0% Much worse than peer group: -13.5% - Net margin
-
-91.9% Much worse than peer group: 0.1% - ROE
-
-331.8% Much worse than peer group: -0.4% - ROA
-
-86.6% Much worse than peer group: 5.1% - Asset turnover
-
94.3% Much worse than peer group: 149.7% - FCF margin
-
-45.7% Much better than peer group: -81.4% - FCF yield
-36.1% - Efficiency ratio
135.9% - Net sales per employee
-
€292.22K - Net income per employee
-
-€268.58K